NDA 021664 · Bausch and Lomb INC
Bromday
Bromfenac Sodium · Ophthalmic
DiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 11, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Mar 24, 2005
Approved uses
3
Original approval plus efficacy supplements
Registered trials
64
15 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 16, 2010 Supplement 13 · Efficacy LabelReviewLetter
- Jan 27, 2006 Supplement 1 · Efficacy LabelLetter
- Mar 24, 2005 Original approval · Type 3 - New Dosage Form ReviewLabelLetter
2 products under this application
- BROMDAY · BROMFENAC SODIUM EQ 0.09% ACID **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION/DROPS, OPHTHALMIC · Discontinued
- XIBROM · BROMFENAC SODIUM EQ 0.09% ACID **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION/DROPS, OPHTHALMIC · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Bromfenac" as an intervention, any sponsor and status, largest first.
- PRevention of Macular EDema After Cataract SurgeryPivotal-lookingCompleted
Maastricht University Medical CenterAcademic, hospital or other
NCT01774474 · 1,127 participants · Start Jul 10, 2013 · Primary completion Nov 4, 2016
Drug: Bromfenac; Dexamethasone and 2 more · For: Cystoid Macular Edema; Cataract; Diabetes Mellitus
Sites: Vienna, Austria; Edegem, Belgium; Frankfurt am Main, Germany · 16 sites in all
- A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye DiseasePivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01212471 · 840 participants · Start Sep 2010 · Primary completion Aug 2011
Drug: Bromfenac Ophthalmic Solution A; Bromfenac Ophthalmic Solution B and 1 more · For: Dry Eye Syndrome
Sites: Irvine, California
- Effectiveness of Periocular Drug Injection in CATaract SurgeryPivotal-lookingTerminated
Luigi RondasAcademic, hospital or other
NCT05158699 · 628 participants · Start Oct 13, 2021 · Primary completion Aug 13, 2024
Drug: Bromfenac; Dexamethasone and 2 more · For: Macular Edema; Cystoid Macular Edema; Retinal Disease and 3 more
Sites: Vienna, Austria; Frankfurt am Main, Germany; Breda, Netherlands · 10 sites in all
- Efficacy and Safety of Bromfenac Ophthalmic SolutionPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00585975 · 568 participants · Start Oct 2007 · Primary completion Jul 2008
Drug: bromfenac ophthalmic solution · For: Cataract Surgery
Sites: Irvine, California
- Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00198445 · 527 participants · Start May 2003 · Primary completion Jan 2004
Drug: Bromfenac; Placebo · For: Postoperative Complications; Cataract
Sites: Birmingham, Alabama; Little Rock, Arkansas; Irvine, California · 39 sites in all
- Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00333918 · 522 participants · Start Jun 2006 · Primary completion Mar 2007
Drug: bromfenac ophthalmic solution; placebo comparator · For: Pain; Inflammation
Sites: Irvine, California
- Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01367249 · 440 participants · Start May 2011 · Primary completion Jul 2011
Drug: Bromfenac Ophthalmic Solution; Placebo · For: Pain; Inflammation; Cataract
Sites: Irvine, California
- Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00853970 · 299 participants · Start Feb 2009 · Primary completion Sep 2009
Drug: Bromfenac Ophthalmic Solution; Placebo Comparator · For: Pain; Inflammation
Sites: Irvine, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients.
Matsumura T, Iwasaki K, Arimura S, et al. · Sci Rep 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema.
Gabr AF, Kamel MF, Elbarawy AA · Int Ophthalmol 2023 · Randomized Controlled Trial
- Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema.
Sahoo S, Barua A, Myint KT, et al. · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.
Kulikov AN, Vasiliev AS, Kalinicheva YA, et al. · BMC Ophthalmol 2024 · Meta-Analysis, Review
- COMPARISON OF THE EFFECTS OF EIGHT DIFFERENT TOPICAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON REDUCING INTRAVITREAL INJECTION-INDUCED PAIN.
SakallioĞlu AK, Kaya S, Garp R, et al. · Retina 2024 · Randomized Controlled Trial, Comparative Study
- Topical NSAIDs effect on corneal sensitivity.
Singer DD, Kennedy J, Wittpenn JR · Cornea 2015 · Randomized Controlled Trial
Sponsor: Bausch and Lomb INC · Also marketed as Xibrom
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.